biostudies-literatureZhang LNational Natural Science Foundation of ChinaMajor Program of National Fund of Philosophy and Social Science of ChinaNational Key Research and Development Program of China9https://www.ebi.ac.uk/biostudies/studies/S-EPMC10924815biostudies-literatureUnknown5(1)Sirolimus is a regularly applied immunosuppressant for patients undergoing liver transplantation (LT) for hepatocellular carcinoma (HCC). Sirolimus not only significantly inhibits HCC recurrence but also protects renal function. However, the improvement effect of sirolimus on nontumour-related death in patients is still unknown. The aim of our study was to investigate the therapeutic effect of sirolimus on nontumour-related deaths. In this study, we retrospectively enrolled 403 LT patients with HCC from January 1, 2015, to December 31, 2018. The median follow-up time was 47.1 months. The patients were divided into the sirolimus group (N = 184) and the sirolimus-free group (N = 219). There were no significant differences between the sirolimus group and the sirolimus-free group in survival (Molecular biomedicinemTOR inhibitor reduces nontumour-related death in liver transplantation for hepatocellular carcinoma.PMC109248152017ZX102032059215920232171368822732702021YFA1100500Ling SHong JLiu PCai JZheng SZhou WZhang LShao CSu RBao JZhan QZhuang LXu XYin LQue QfalsemTOR inhibitor reduces nontumour-related death in liver transplantation for hepatocellular carcinoma.Sirolimus is a regularly applied immunosuppressant for patients undergoing liver transplantation (LT) for hepatocellular carcinoma (HCC). Sirolimus not only significantly inhibits HCC recurrence but also protects renal function. However, the improvement effect of sirolimus on nontumour-related death in patients is still unknown. The aim of our study was to investigate the therapeutic effect of sirolimus on nontumour-related deaths. In this study, we retrospectively enrolled 403 LT patients with HCC from January 1, 2015, to December 31, 2018. The median follow-up time was 47.1 months. The patients were divided into the sirolimus group (N = 184) and the sirolimus-free group (N = 219). There were no significant differences between the sirolimus group and the sirolimus-free group in survival (2024-01-01T00:00:00Z2024 Mar2025-04-04T12:59:04.354Z2025-04-04T12:59:04.354ZS-EPMC109248153846120610.1186/s43556-024-00170-6